Skip to main content

Table 1 The dosimetric comparison for the VMAT versus the IMPT plans

From: Dosimetric evaluation of photons versus protons in postmastectomy planning for ultrahypofractionated breast radiotherapy

Organs

Dose levels

Lt. chest wall + regional nodes

Lt. chest wall

Rt. chest wall + regional nodes

Rt. chest wall

IMPT

VMAT

P value

IMPT

VMAT

P value

IMPT

VMAT

P value

IMPT

VMAT

P value

PTV

Dmax (GyRBE)

29.0 ± 1.0

28.0 ± 0.8

< 0.05

29.33 ± 1.4

28.1 ± 0.8

< 0.05

28.1 ± 0.8

27.4 ± 0.7

0.1

28.3 ± 1.1

26.4 ± 3.1

0.1

D90 (GyRBE)

25.8 ± 0.3

25.6 ± 0.3

0.2

25.8 ± 0.6

25.4 ± 0.3

< 0.05

25.30 ± 0.51

25.4 ± 0.2

0.4

25.4 ± 0.5

25.3 ± 0.2

0.3

D95 (GyRBE)

24.8 ± 0.1

24.8 ± 0.4

0.9

24.8 ± 0.2

24.7 ± 0.2

0.2

24.6 ± 0.2

24.7 ± 0.3

0.4

24.8 ± 0.5

24.9 ± 0.8

0.6

Ipsi-lung

Dmean (GyRBE)

8.3 ± 1.3

7.9 ± 1.7

0.4

7.4 ± 1.9

7.8 ± 0.8

0.5

7.3 ± 1.2

7.9 ± 2.7

0.5

6.9 ± 1.7

8.0 ± 1.2

0.1

V5 (%)

55.1 ± 9.2

54.6 ± 11.9

0.9

49.3 ± 10.5

54.2 ± 7.0

< 0.05

47.6 ± 8.1

57.1 ± 10.9

< 0.05

44.6 ± 10.5

52.7 ± 12.1

0.1

V10 (%)

39.3 ± 7.2

27.3 ± 8.2

< 0.05

33.3 ± 7.7

26.5 ± 4.0

< 0.05

34.8 ± 9.4

31.9 ± 4.5

0.4

29.6 ± 5.4

27.9 ± 6.4

0.4

V20(%)

9.7 ± 3.7

7.6 ± 4.7

< 0.05

8.5 ± 5.9

6.4 ± 3.0

0.2

9.6 ± 3.4

8.2 ± 3.6

0.1

9.6 ± 4.3

8.3 ± 3.9

0.3

Contra-lung

Dmean (GyRBE)

0.2 (0.1–0.3)

3.4 (2.9–3.7)

< 0.05

0.1 (0.1–0.2)

3.1 (2.7–4.0)

< 0.05

0.1 (0.0–0.1)

3.1 (2.9–3.2)

< 0.05

0.0 (0.0–0.1)

2.6 (2.4–3.0)

< 0.05

V5 (%)

0.6 (0.2–1.2)

20.9 (14.5–25)

< 0.05

0.4 (0–0.9)

14.1(11.1–26.8)

< 0.05

0 (0–0)

15.8 (12.4–18.7)

< 0.05

0 (0–0)

10.9 (9.4–15)

< 0.05

V10 (%)

0.1 (0–0.3)

0.9 (0.6–2.1)

< 0.05

0 (0–0)

0.8 (0.4–1.5)

< 0.05

0 (0–0)

0 (0–0)

< 0.05

0 (0–0)

0.4 (0.2–0.6)

< 0.05

Heart

Dmax (GyRBE)

16.9 ± 7.0

19.9 ± 4.2

< 0.05

16.9 (10.4–25.5)

18.6 (18.3–22.0)

0.3

10.6 ± 4.8

10.1 ± 4.8

0.7

8.4 (4.8–13.4)

11.2 (8.4–14.5)

0.4

Dmean (GyRBE)

1.1 (0.6–2.0)

4.6 (4.4–4.7)

0.1

1.2(0.7–1.5)

5 (4.6–5.6)

< 0.05

0.4 (0.3–0.7)

2.8 (2.2–3.4)

< 0.05

0.5 (0.2–0.8)

3.3 (2.5–3.5)

< 0.05

V5 (%)

7.5 ± 4.0

28.2 ± 10.9

< 0.05

8.6 (4.6–10.2)

33 (26.3–40.2)

< 0.05

2.3 (1.6–4.7)

10.6 (5.4–17.1)

< 0.05

2.3 (0.5–5.6)

16.3 (6–17.8)

< 0.05

V10 (%)

3.5 (1–6.3)

8.5 (7.4–11.8)

< 0.05

4 (1.1–5.2)

12 (8.3–14.4)

< 0.05

1.2 (0.2–2.2)

1.7 (0–3)

0.64

0.2 (0–1.2)

1.1 (0–2.5)

0.4

V20 (%)

0.4 (0–0.8)

0.5 (0.4–1.7)

0.1

0.3 (0–0.6)

0.5 (0.2–0.6)

0.2

0 (0–0)

0 (0–0)

0.6

0 (0–0.1)

0 (0–0)

0.1

Skin

Dmax (GyRBE)

28.4 ± 1.2

27.3 ± 0.9

0.1

28.4 ± 1.9

27.3 ± 0.8

< 0.05

28.2 ± 1.1

26.8 ± 0.6

< 0.05

28.2 ± 1.4

26.8 ± 0.6

< 0.05

Dmean (GyRBE)

24.5 ± 1.1

23.4 ± 1.0

< 0.05

24.7 ± 1.7

23.2 ± 0.9

< 0.05

25.2 ± 1.7

23.3 ± 0.7

< 0.05

24.9 ± 0.8

23.3 ± 0.6

< 0.05

Esophagus

Dmax (GyRBE)

24.2 ± 2.3

22.0 ± 4.2

< 0.05

2.0 (0.6–3.8)

8.7(8.3–9.6)

< 0.05

19.8 ± 4.3

19.4 ± 4.3

0.7

0.2 (0.1–2.4)

7.9 (5.6–9.8)

< 0.05

Dmean (GyRBE)

4.5 ± 1.7

7.0 ± 1.7

< 0.05

0.2 (0.1–0.4)

3.4 (2.8–3.5)

< 0.05

2.9 ± 1.2

5. 7 ± 0.9

< 0.05

0 (0–0.2)

2.9 (2.5–3.0)

< 0.05

Thyroid

Dmax (GyRBE)

27.7 ± 1.1

27.1 ± 1.0

0.1

1.8(1.2–2.8)

0.8 (0.7–1)

0.0

26.1 ± 2.0

25.2 ± 3.9

0.4

0.6 (0.0–1.6)

0.8 (0.7–1.0)

0.9

Dmean (GyRBE)

13.5 ± 6.0

16.3 ± 4.5

0.4

0.2 (0.1–0.3)

0.5 (0.4–0.6)

< 0.05

12.5 ± 2.7

14.8 ± 1.9

< 0.05

0.1 (0–0.3)

0.5 (0.4–0.6)

< 0.05

  1. Mean ± SD for normally distributed data using a paired t-test; median (IQR) for nonnormally distributed data using the Wilcoxon signed-rank test